Navigation Links
Anavex advances drug candidate for treatment of Alzheimer's disease
Date:11/28/2007

ease. The brains of mice were injected with amyloid beta peptide, the key ingredient in Alzheimer's brain plaques, which is known to induce histological and biochemical changes, oxidative stress and learning deficits within seven days.

When ANAVEX 1-41 was administered to mice during pre-clinical testing, the compound dose prevented amyloid-beta-induced learning in the spontaneous alternation and passive avoidance performances. In addition, it blocked the induction of amyloid-beta-induced lipid peroxidation, the biochemical process that mediates damage to nerve cell membranes. ANAVEX 1-41 also reduced the loss of pyramidal cells in the hippocampus and blocked the amyloid-beta-induced expression of caspase-3.

ANAVEX 1-41 has been previously shown to reverse learning deficits in mice that were induced by the drugs scopolamine and dizocilpine, or through the administration of amyloid beta peptide. In addition to these findings, the ANAVEX scientific team recently reported the neuroprotective potential of sigma-1 receptor drugs due to their sigma-1 receptor modulatory role on calcium mobilization and signal transduction pathways.

"We are excited by the data that was presented at the Neuroscience 2007 conference regarding the neuroprotective and anti-amnesic properties of ANAVEX 1-41 for Alzheimer's disease," said Dr. Kontzalis, Chief Executive Officer for ANAVEX. "We are committed to further exploring the disease-modifying properties of ANAVEX 1-41 and to meeting our ultimate goal of developing novel therapies to prevent the onset of or slow the progression of Alzheimer's disease."

ANAVEX 1-41 pre-clinical studies will be completed in the coming weeks. Once pre-clinical testing is complete, ANAVEX will commence with IND filing so that human trials of ANAVEX 1-41 can begin.

About Alzheimer's disease

Alzheimer's disease is the most common cause of dementia and is characterized by the progressive degeneration of cognition as a resu
'/>"/>

SOURCE Anavex Life Sciences Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
2. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
3. Verenium Advances Its Development Work With Cargill on a New Food-Related Product
4. EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference
5. Response Genetics CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference
6. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
7. KineMed to Collaborate With Merck KgaA to Validate New Applications for Drug Development Candidates
8. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
9. BioSpace Draws Over 600 Candidates to San Diego Life Science Career Fair
10. Astex Drug Candidates to be Featured at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
11. First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... , March 3, 2015  RegeneRx Biopharmaceuticals, Inc. ... in the scientific journal, Expert Opinion on Biological ... colleague, Dr. Zhenggang Zhang , at the Henry ... reported that Thymosin beta 4 (TB4) has the capacity ... 24 hours or more post-injury, leading to neurological recovery ...
(Date:3/3/2015)... New Jersey (PRWEB) March 03, 2015 ... has announced today that it has acquired The ... Terms of the transaction were not announced. , ... services to the energy sector including oil and ... energy, and fossil and nuclear power sectors. The ...
(Date:3/3/2015)... 03, 2015 Research and Markets ... Jain PharmaBiotech,s new report "Gene Therapy - ... , Gene therapy technologies are ... and cell therapy with genetically modified vectors. Gene ... and various routes of administration as well as ...
(Date:3/3/2015)... , March 3, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... sustainable chemicals, today announced it has initiated commissioning activities ... in Sarnia, Ontario , Canada.  ... approximately five months, with the facility being in commercial ... be completed in two months and it is carrying ...
Breaking Biology Technology:Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 2Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 3BioAmber Begins Commissioning of Sarnia Commercial Plant 2BioAmber Begins Commissioning of Sarnia Commercial Plant 3
... INDIANAPOLIS, March 7 Eli Lilly and Company,(NYSE: ... its AIR(R),Insulin program, which was being conducted in partnership ... clinical development as a potential,treatment for type 1 and ... not a result of any observations during AIR Insulin ...
... Kendle (Nasdaq: KNDL ), a,leading, global ... Executive Officer Candace Kendle, PharmD, and,President and Chief ... to sell shares of the company,s common stock ... part of their personal,ongoing long-term strategy for tax ...
... treatment ... disease, BIRMINGHAM, Ala., March 7 Atherotech, Inc., a,cardio-diagnostic ... in Booth 21041 at the American College of Cardiology,(ACC) 57th ... 1, 2008, at the McCormick Place Convention Center in,Chicago, Ill., ...
Cached Biology Technology:Lilly Announces Termination of AIR Insulin Program 2Lilly Announces Termination of AIR Insulin Program 3Lilly Announces Termination of AIR Insulin Program 4Kendle Leaders Adopt 10b5-1 Trading Plans 2Atherotech to Exhibit the VAP Test (R) at ACC 2008 Meeting in Chicago 2
(Date:3/2/2015)... VILNIUS, Lithuania , March 2, 2015   ... AI technologies, today introduced the SentiGaze Software Development ... developers to create applications that use off-the-shelf webcams to ... a user gazes at a monitor. Heatmaps can be ... determining the effectiveness of online advertising. The SDK can ...
(Date:2/23/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announced today ... DISTRIBUTED VOICE DIRECTED PAYMENT METHOD AND SYSTEM. ... payment method. Payment accounts may be selected via voice ... if both the speech (the word associated with the ...
(Date:2/12/2015)... , Feb. 12, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... filed provisional patent 62/113114 for DISTRIBUTED METHOD ... The patent further establishes NXT-ID,s position in ... intellectual property portfolio the ability for multiple devices to ...
Breaking Biology News(10 mins):Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3
... funded by the Office of Naval Research (ONR) were ... Engineers (PECASE), the nation,s highest honor for young scientists ... selection of these six individuals underscores ONR,s fundamental objective, ... by leveraging the ideas of the best and brightest ...
... is available in German . , ... more complex structures and better-adapted organisms. This is all ... Especially in small asexual populations that do not recombine ... known as Muller,s ratchet in evolutionary biology. The ratchet, ...
... scientists like it when the results of measurements fit with ... and compare their values, the results are rarely "smooth". A ... is: how much nitrogen is being fixed in the ocean ... is important to predicting future climate development. All organisms need ...
Cached Biology News:ONR-funded young innovators recognized by President 2Populations survive despite many deleterious mutations 2Populations survive despite many deleterious mutations 3How much nitrogen is fixed in the ocean? 2
Anti-gp340 Monoclonal Antibody Description: 100 g Research Focus: cancer & cell proliferation Storage: -20C Shipping Temperature: 4C...
Mouse anti-HIV-Imn PND Class: Antibody Product Group: Bacterial and Viral Antigen...
... BRF2 Immunogen Synthetic peptide: QAARQAATSVPNPP, corresponding ... BRF2. Reactivity / Specificity Cross-reacts with ... Background Information BRF2 is one of the ... factor complex required for transcription of genes with ...
Kinase Buffer can be used to assay protein kinase activity...
Biology Products: